News & Updates

Many paediatric sexual assault victims do not receive hepatitis B virus (HBV) postexposure vaccination and have low compliance to HIV postexposure prophylaxis (PEP), reveals a study in Singapore.

Twice-yearly subcutaneous (SC) lenacapavir demonstrates high efficacy, favourable safety, and consistent pharmacokinetics (PK) as pre-exposure prophylaxis (PrEP) for HIV-negative youth (aged 16–25 years) in an analysis of the phase III PURPOSE 1 (P1) and PURPOSE 2 (P2) trials.

Attention deficit/hyperactivity disorder (ADHD) is frequently under-reported, says Dr Serena In, Clinical Psychologist and Senior Lecturer at the IMU University.